Initial treatment of epilepsy: Special issues in treating the elderly

Neurology

Volumn 63, Issue 10 SUPPL. 4, 2004, Pages

  Bergey, Gregory K ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; CARBAMAZEPINE; CIMETIDINE; DEXTROPROPOXYPHENE; DILTIAZEM; ERYTHROMYCIN; ESTROGEN; ETIRACETAM; FLUOXETINE; GABAPENTIN; ISONIAZID; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PRIMIDONE; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; TRAZODONE; VALPROIC ACID; VERAPAMIL; WARFARIN; ZONISAMIDE;

AGED; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; FOCAL EPILEPSY; GAIT DISORDER; GERIATRIC CARE; HUMAN; HYPERAMMONEMIA; HYPONATREMIA; INCIDENCE; IRRITABILITY; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; MEDICAL DECISION MAKING; MENTAL DISEASE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BINDING; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; TREMOR; WEIGHT GAIN;

EID: 8844248524     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.10_suppl_4.s40     Document Type: Review

References (56)

1. Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia 1995;36:327-333.
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453-468.
3. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004;62(suppl 2):S24-29.
4. Hiyoshi T, Yagi K. Epilepsy in the elderly. Epilepsia 2000;41(suppl 9):31-35.
5. Asconape JJ, Penry JK. Poststroke seizures in the elderly. Clin Geriatr Med 1991;7:483-492.
6. McAreavey MJ, Ballinger BR, Fenton GW. Epileptic seizures in elderly patients with dementia. Epilepsia 1992;33:657-660.
7. Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003;20:791-803.
8. Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology 1996;46:727-730.
9. Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004;363:1184-1186.
10. Hauser WA, Anderson VE, Loewenson RB, McRoberts SM. Seizure recurrence after a first unprovoked seizure. N Engl J Med 1982;307:522-528.
11. Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 1990;40:1163-1170.
12. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42:1255-1260.
13. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151.
14. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-771.
15. Brodie MJ, Chadwick DW, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.
16. Kwan P, Sills GJ, Butler E, Gant TW, Brodie MJ. Differential expression of multidrug resistance genes in naive rat brain. Neurosci Lett 2003;339:33-36.
17. Morrell MJ, McLean MJ, Willmore LJ, et al. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group. Seizure 2000;9:241-248.
18. Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003;4:702-709.
19. Morrell MJ, Leppik I, French J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003;54:153-161.
20. Ramsay RE, Rowan AJ, Pryor FM, Collins JF, and the DVA Coop Study Group 428. Treatment of seizures in the elderly: final analysis from DVA Cooperative Study #428. Epilepsia 2004;44(suppl 9):170. Abstract.
21. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-87.
22. French JA, Schachter S. A workshop on antiepileptic drug monotherapy indications. Epilepsia 2002;43(suppl 10):3-27.
23. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273.
24. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-1260.
25. Cloyd J. Commonly used antiepileptic drugs: age-related pharmacokinetics. In: Rowan AJ, Ramsay RE, eds. Seizures and epilepsy in the elderly. Boston: Butterworth-Heinemann, 1997:219-237.
26. Lackner TE, Cloyd JC, Thomas LW, Leppik IE. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia 1998;39:1083-1087.
27. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989;39:1587-1588.
28. Pugh MJ, Cramer J, Knoefel J, et al. Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. J Am Geriatr Soc 2004;52:417-422.
29. Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003;60:555-559.
30. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug use in nursing home admissions. Ann Neurol 2003;54:75-85.
31. Ragueneau-Majlessi I, Bajpai M, Levy RH. Phenytoin and other hydantoins: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. Philadelphia: Lippincott Williams & Wilkins, 2002:581-590.
32. Wurden CJ, Levy RH. Carbamazepine: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. Philadelphia: Lippincott Williams & Wilkins, 2002:247-261.
33. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with Carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994;35:181-188.
34. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Neurology 1997;48:182-188.
35. Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996;46:465-469.
36. Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia 2002;43:1421-1424.
37. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002;40:789-801.
38. Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Currents 2003;3:91-95.
39. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8:339-342.
40. Ensrud KE, Walczak TS, Blackwell T, et al. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-2057.
41. Meador KJ, Gilliam FG, Kanner AM, Pellock JM. Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 2001;2:SS1-17.
42. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003;61:1218-1221.
43. Leiderman DB. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia 1994;35(suppl 5):S74-76.
44. Alsaadi TM, Koopmans S, Apperson M, Farias S. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure 2004;13:58-60.
45. Cramer JA, Leppik IE, Rue KD, Edrich P, Kramer G. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003;56:135-145.
46. Messenheimer J, Mockenhaupt M, Tennis P, Schlingmann J. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis among new users of antiepileptic drugs. Neurology 2004;62(suppl 5): A352-353. Abstract.
47. Anderson GD, Gidal BE, Messenheimer JA, Gilliam FG. Time course of lamotrigine deinduction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 2002;49:211-217.
48. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003;57:85-93.
49. Hahn CG, Gyulai L, Baldassano CF, Lenox RH. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry 2004;65:791-804.
50. Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: systematic review and meta-analysis. Am J Psychiatry 2003;160:1147-1156.
51. Gilliam FG, Santos J, Vahle V, et al. Depression in epilepsy: ignoring clincical expression of neuronal network dysfunction. Epilepsia 2004;45(suppl 2):28-33.
52. Bourgeois B, D'Souza J. Safety and tolerability of oxcarbazepine in children with epilepsy. Epilepsia 2003;44(suppl 9):275. Abstract.
53. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003;4:175-180.
54. Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002;51:613-620.
55. Pedersen B. Epilepsy in the elderly: the use of tiagabine. Epilepsia 2001;42(suppl 3):52-54.
56. Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series. Treatment of epilepsy. Epilepsy Behav 2001;2(suppl):A1-50.